C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
US5494671A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 20, 1991 |
| Grant date | Feb 27, 1996 |
| Priority date | — |
| Expiry date | Aug 20, 2011 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/826
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to C-terminally truncated flavivirus envelope proteins 80-81% in size which are more immunogenic than their counterpart full-length proteins. The present invention further relates to recombinant viruses which encode the truncated protein and to host cells infected therewith. Host cells express the truncated protein on their outer membrane and secrete it into the medium. The present invention further relates to vaccines for use against flavivirus infection. The vaccines include either a recombinant vaccinia virus expressing the truncated envelope protein of the present invention, and the truncated envelope protein produced by a recombinant baculovinis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.